CLAIMS

What is claimed is:

1. A composition comprising a therapeutically effective amount of SEQ ID NO: 3 and a lipid-based carrier.

2. The composition of claim 1, wherein the lipid-based carrier comprises lipid micelles.

3. The composition of claims 1 or 2, wherein the lipid-based carrier comprises a lipid emulsion.

4. The composition of claim 3, wherein the lipid-based carrier is present in an amount of about 10% w/v to about 20% w/v.

5. A composition comprising a therapeutically effective amount of SEQ ID NO: 2 or SEQ ID NO: 3 and at least one excipient.

6. The composition of claim 5, wherein the at least one excipient is suitable for intravenous administration.

7. The composition of claims 5 or 6, wherein the at least one excipient is selected from the group consisting of a citrate, an ascorbate, amino acids, and combinations thereof.

8. The composition of claim 7, wherein the citrate comprises sodium citrate.

9. The composition of claim 8, wherein the citrate is present in an amount of ~~about~~ 1% w/v to ~~about~~ 5% w/v.

10. The composition of claim 7, wherein the ascorbate comprises sodium ascorbate.

11. The composition of claim 10, wherein the ascorbate is present in an amount of ~~about~~ 1% w/v to ~~about~~ 5% w/v.

12. The composition of claim 7, wherein the amino acids comprise L-methionine.

13. The composition of claim 12, wherein the amino acids are present in an amount of ~~about~~ 0.01% w/v to ~~about~~ 5% w/v.

14. The compositions of any of claims 1-13, wherein SEQ ID NO: 2 or SEQ ID NO: 3 is present in an amount of ~~about~~ 0.001 to ~~about~~ 200 milligrams per kilogram (mg/kg) of body weight.

15. The composition of any of claims 1-14, wherein SEQ ID NO: 2 and/or SEQ ID NO: 3 is present in an amount of ~~about~~ 5 to ~~about~~ 160 mg/kg.

16. The composition of any of claims 1-13, wherein SEQ ID NO: 2 or SEQ ID NO: 3 is present in an amount of ~~about~~ 1 mg/ml to ~~about~~ 100 mg/ml.

17. The composition of any of claims 1-13, wherein SEQ ID NO: 2 or SEQ ID NO: 3 is present in an amount of ~~about~~ 10 mg/ml to ~~about~~ 80 mg/ml.

18. A ~~method of altering cytokine expression comprising administering to a subject in need thereof a~~ composition according to any of claims 1-17 for use in therapy.

19. The ~~method~~ composition of claim 18, wherein the ~~administration comprises~~composition is formulated for parenteral administration.

20. The ~~method~~ composition of claim 18 or 19, wherein the ~~administration comprises~~composition is formulated for intravenous administration.

21. Use of ~~A method of treating or preventing a disease or condition comprising administering to a subject in need thereof~~ a composition according to any of claims 1-17 in the manufacture of a medicament for treating or preventing a disease or condition.

22. The ~~method~~ use of claim 21, wherein the ~~administration comprises~~medicament is to be administered via parenteral administration.

23. The ~~method~~ composition of claim 21 or 22, wherein the medicament is to be administered via ~~administration comprises~~ intravenous administration.